May, 2022

article thumbnail

New £20m Life Sciences Fund Launches to Support SMEs In Greater Manchester, Cheshire and Warrington

Drug Discovery Today

‘GMC Life Sciences Fund by Praetura’ aims to bolster Greater Manchester and Cheshire and Warrington’s flourishing life sciences sector. The fund, raised by partners including Bruntwood SciTech, Greater Manchester Combined Authority (GMCA) and Cheshire and Warrington Local Enterprise Partnership (LEP), will be deployed by Manchester-based Praetura Ventures.

Science 113
article thumbnail

The GoodRx-Kroger Blowup: Spread Pricing, Pharmacy Margins, and the Future of Discount Cards

Drug Channels

A few weeks ago, GoodRx surprised investors with the unpleasant news that a major grocery chain had stopped accepting its discount card for an unspecified number of prescriptions. As I explain below, the unnamed chain appears to be Kroger— the sixth-largest U.S. pharmacy. What’s more, GoodRx disclosed that Kroger accounts for an unexpected one-quarter of its prescription business.

article thumbnail

DrugPatentWatch named “Best of the Web” by Genetic Engineering News

Drug Patent Watch

DrugPatentWatch has been named to Genetic Engineering News‘ Best of the Web list. The review by Genetic Engineering News profile highlighted the “new training modules designed to help you find…. The post DrugPatentWatch named “Best of the Web” by Genetic Engineering News appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Denali Therapeutics and Biogen Announce Initiation of Phase 2b Study of LRRK2 Inhibitor in Parkinson’s Disease

The Pharma Data

BIIB122 is an inhibitor of LRRK2, a potential novel target intended to impact the underlying biology and slow the progression of Parkinson’s disease Phase 2b LUMA to enroll approximately 640 participants with early-stage Parkinson’s disease; most advanced clinical study of a LRRK2 inhibitor. Denali Therapeutics Inc. (NASDAQ: DNLI), and Biogen Inc. (NASDAQ:BIIB) today announced that dosing has commenced in the global Phase 2b LUMA study to evaluate the efficacy and safety of BIIB122 (DNL151), as

Disease 52
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

Accelerating digital transformation: Taking the lead on data and process standardization

The Connected Lab

Digital transformation is revolutionizing pharmaceutical research and manufacturing. Driven by technologies such as advanced automation, smart sensors, artificial intelligence and machine learning, digital transformation provides new opportunities for organizations to streamline workflows, boost productivity and improve quality throughout the value chain.

article thumbnail

How Lorenzo Bomba is using rare genetic variants to understand blood metabolites

The Open Targets Blog

Lorenzo Bomba was a postdoctoral fellow in the Soranzo group, which uses large-scale genomic analysis to study the human variation linked to cardiometabolic traits and diseases. He recently published the results of an Open Targets project  which found new associations between genes and blood metabolites in the American Journal of Human Genetics.

Disease 52

More Trending

article thumbnail

Gross-to-Net Bubble Update: 2021 Pricing Realities at 10 Top Drugmakers

Drug Channels

Time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. This year’s review includes 10 companies: Eli Lilly and Company, Genentech, GlaxoSmithKline, Janssen, Merck, Novartis, Novo Nordisk, Sanofi, Takeda, and UCB. You can find links to each company’s data below. When rebates and discounts were factored in, brand-name drug prices declined—or grew slowly—in 2021.

article thumbnail

New patent for Ironwood Pharms drug DUZALLO

Drug Patent Watch

Annual Drug Patent Expirations for DUZALLO Duzallo is a drug marketed by Ironwood Pharms Inc and is included in one NDA. There are nine patents protecting this drug. DUZALLO drug…. The post New patent for Ironwood Pharms drug DUZALLO appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 91
article thumbnail

AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 2 DATA FOR INVESTIGATIONAL OLPASIRAN IN ADULTS WITH ELEVATED LIPOPROTEIN(a)

The Pharma Data

Study Showed Significant, Sustained Reduction in Lipoprotein(a) During Treatment Period. Lipoprotein(a) Reduction was Consistent With Phase 1 Results. Amgen (NASDAQ:AMGN) today announced positive topline data from the Phase 2 OCEAN(a)-DOSE clinical study, evaluating olpasiran (formerly AMG 890) in 281 adult patients with Lipoprotein(a), or Lp(a), levels over 150 nmol/L and evidence of atherosclerotic cardiovascular disease (ASCVD).

RNA 52
article thumbnail

What are analytical method development services?

Altus Drug Development

From natural health products to life-saving medicines, all pharmaceutical products must undergo an analytical method development process. Through analytical method development, validation, and transfer, drug development and manufacturing are kept safe, efficient, and compliant with the law. What is analytical method development? Analytical method development is the creation of a set of experimental conditions to perform analytical procedures in chemical samples.

article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

5 Must-Attend BIO Sessions on Partnering with Academia

Translation

Thanks to a spotlight from the Covid-19 pandemic, the biotechnology industry attracted record investment in 2020 and 2021. But maintaining that edge will require building more talent and improving commercial development and execution, according to McKinsey. One competitive differentiator: deepening relationships between academia and industry. This June’s BIO International Convention in San Diego is crammed with 100+ sessions in just four days.

article thumbnail

Patient centricity in drug innovation and packaging design to take centre stage at Connect in Pharma in Geneva this September

Drug Discovery Today

Talk from Roche engineer Tiffany McIntire will highlightopportunities for the pharma sector to reinvent packaging to bemore focused on patient needs in areas such as medication takenorally

Packaging 100
article thumbnail

It’s Time to Put Innovative Contracts Under Warranty

Drug Channels

Today’s guest post comes from Jane Barlow, Chief Clinical Officer, and Susan Raiola, President of Real Endpoints. Jane and Susan discuss the mechanism and benefits of warranties in the realm of value-based contracts. To learn more about payer-pharma warranty contracts and whether these agreements can solve issues that limit the utility of more traditional value-based contracts, sign up for Real Endpoints’ free June 9 webinar: Putting Innovative Contracts Under Warranty.

Drugs 86
article thumbnail

Which pharmaceutical drugs have the most drug patents in Ireland?

Drug Patent Watch

This chart shows the drugs with the most patents in Ireland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Ireland? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.

article thumbnail

Takeda and Moderna Announce Plans to Transfer Marketing Authorization for SpikevaxTM COVID-19 Vaccine in Japan to Moderna

The Pharma Data

– Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance and commercial activities for Spikevax TM from 1st August 2022 – Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period.

Vaccine 52
article thumbnail

What are value-added medicines?

Altus Drug Development

Value-added medicines offer the medical world the opportunity to increase the quality of treatments as well as expand access to healthcare for more people. By improving the efficiency of the healthcare system, value-based healthcare contributes to its sustainability, addresses inefficiencies related to medicines, and offers economic advantages to all parties involved in medical treatments.

article thumbnail

R&D Partnering Testimonials from Bayer, Oldcastle and Joyn Bio

Translation

Companies invest more than $2 trillion in R&D annually to stay ahead of competition, identify new products, and find new sources of revenue. These R&D efforts are fundamental to solving some of the world’s most challenging problems like combating climate change and curing diseases. Today, 80% of companies that invest in R&D partner with outside innovators.

article thumbnail

Getting Better With Age – Conference Set To Tackle UK’s “Ticking Time Bomb” of Age-Related IllnessesAlderley Park conference aims to improve therapeutics for the UK’s ageing population

Drug Discovery Today

Medicines Discovery Catapult (MDC) is hosting UK SPINE, ‘Healthspan vs. lifespan: New medicines to close the gap’ - a conference on ageing, which aims to tackle one of the UK’s most pressing healthcare challenges.

100
100
article thumbnail

Clinical Data Like You´ve Never Seen It Before: Why Spotfire Is the Leading Tool for Clinical Analytics

Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic

article thumbnail

Opportunities to Improve Critical Medication Access in Oncology

Drug Channels

Today’s guest post comes from Shawn Seamans, Chief Commercial Officer at CoverMyMeds. Shawn discusses the unique challenges cancer patients face in accessing, affording, and adhering to treatment. He explains how patient-centric technology, combined with access to caring experts, can alleviate these challenges. Read more about access, affordability, and adherence opportunities for oncology patients in the CoverMyMeds 2022 Medication Access Report: Oncology Edition.

article thumbnail

Capsule dosed drug patent expirations by year

Drug Patent Watch

This chart shows the patent expirations for capsule dosed drugs over the next decade. The term of drug patents varies. The basic term for a patent is 20 years from…. The post Capsule dosed drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 89
article thumbnail

Sandoz announces new global ‘Act4Biosimilars’ initiative, to improve patient access and increase adoption by at least 30% in 30+ countries by 2030

The Pharma Data

Multidisciplinary Steering Committee established to drive action includes patient advocacy leaders, healthcare professionals, biosimilar experts and industry leaders Action Plan will provide roadmap and tools to improve approvability, accessibility, acceptability and affordability (4As) of biosimilars Sandoz launched initiative to support improved healthcare access, equity and sustainability.

article thumbnail

What value-added medicines might bring to society

Altus Drug Development

Everyone is interested in having access to the best healthcare available. However, many patients end up having to face the fact that many treatments are unfeasible, too expensive, or potentially counter-conducive. Knowledge of issues within the healthcare system is not unknown to those in charge. However, dealing with them often requires making structural changes many industry players are not willing or able to perform.

article thumbnail

Antibody-drug Conjugate: A “Biological Missile” for Tumor Targeted Therapy

Creative Biolabs

Cancer has become the second largest health threat in the world, with about 10 million people dying of cancer in 2020. For decades, cytotoxic-based chemotherapy has been the main treatment for all kinds of cancers. These cytotoxic drugs include DNA base analogs, antimetabolic drugs, tubulin inhibitors, etc. However, most of these chemotherapeutic drugs show a low therapeutic index, and serious side effects are usually attributed to the exposure of non-specific drugs to off-target tissues.

article thumbnail

Evonetix Granted Patent for Binary Assembly Method for Gene Synthesis

Drug Discovery Today

IP covers novel method for assembly and error removal in DNA synthesis on silicon chips.

DNA 113
article thumbnail

The State of Specialty Pharmacy 2022: Reflections, Trends, and Photos from #Asembia22

Drug Channels

Two weeks ago, Paula and I had the pleasure of attending Asembia’s 2022 Specialty Pharmacy Summit at the wonderful Wynn Las Vegas. Below, I violate Vegas code and tell you what happened there. I offer reflections on my keynote session with Scott Gottlieb, share my experiences during the featured session, and highlight three crucial specialty industry trends.

article thumbnail

Which pharmaceutical companies have the most drug patents in Ireland?

Drug Patent Watch

This chart shows the pharmaceutical companies with the most patents in Ireland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Ireland? appeared first on DrugPatentWatch - Make Better Decisions.

article thumbnail

FDA accepts Dupixent® (dupilumab) for priority review in adults with prurigo nodularis

The Pharma Data

FDA accepts Dupixent ® (dupilumab) for priority review in adult s with prurigo nodularis. Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved Acceptance marks another important step in advancing Dupixent for a broad range of diseases with underlying type 2 inflammation. The U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) to

FDA 52
article thumbnail

Planning Clinical Trial in USA? Here is what you should know

ProRelix Research

The United States has always been and remains to be the leading place for the conduct of clinical trials. According to Clinicaltrials.gov, the largest clinical trials registry, 32% of registered […]. The post Planning Clinical Trial in USA? Here is what you should know appeared first on ProRelix Research.

article thumbnail

The ROI of eRegulatory and eIRB Integration

Advarra

Compliant, efficient document management during the various phases of a clinical trial is essential. Yet, throughout a trial, as documents are added to different systems for the investigator/institution and the sponsor, a great deal of time is spent managing those documents; and, of course, as with any manual process, there’s risk of error. That’s why direct communication and integration between key technology systems like email, electronic institutional review board (eIRB) systems, clinical tri

article thumbnail

Mental Health Awareness Month: Tips for Maintaining Mental Health

Olympian Clinical Research

May is Mental Health Awareness Month , so there’s no better time to focus on our mental health and well-being. Good mental health is essential to our overall well-being and happiness, so it’s essential to do what we can to maintain it. To honor Mental Health Awareness Month, we have come up with a list of tips to help our patients and community members like you keep their mental health in optimal shape. 1.

article thumbnail

DCI’s Top 15 Specialty Pharmacies of 2021—And Three Factors That Will Reshape 2022

Drug Channels

In Drug Channels Institute’s list of the top 15 pharmacies of 2021 , we show that central-fill, mail pharmacies operated by large PBMs and health insurers have displaced retail chains as the largest prescription drug dispensers by revenues. To complement that broader ranking, we present below our exclusive and updated list of the top 15 pharmacies based on specialty drug dispensing revenues in 2021.

article thumbnail

New patent expiration for Purdue Pharma drug TARGINIQ

Drug Patent Watch

Annual Drug Patent Expirations for TARGINIQ Targiniq is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are fifteen patents protecting this drug. Drug patent…. The post New patent expiration for Purdue Pharma drug TARGINIQ appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 86
article thumbnail

BlueRock Therapeutics Announces Completion of Enrollment of Phase 1 Trial in Patients with Parkinson’s Disease

The Pharma Data

Initiation of global non-interventional study for patients with Parkinson’s planned for the second half of 2022 as next step. BlueRock Therapeutics LP, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer?AG, announced?the completion of enrollment of its Phase 1 (Ph1), open-label trial of pluripotent stem cell-derived dopaminergic neurons in patients with Parkinson’s disease (PD).

Trials 52